These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
263 related articles for article (PubMed ID: 29495003)
1. Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression. Liu Y; Zhang RX; Yuan W; Chen HQ; Tian DD; Li H; Jiang X; Deng ZL; Wang Y Cell Physiol Biochem; 2018; 45(5):1759-1771. PubMed ID: 29495003 [TBL] [Abstract][Full Text] [Related]
2. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis. Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538 [No Abstract] [Full Text] [Related]
3. Bone Cell-autonomous Contribution of Type 2 Cannabinoid Receptor to Breast Cancer-induced Osteolysis. Sophocleous A; Marino S; Logan JG; Mollat P; Ralston SH; Idris AI J Biol Chem; 2015 Sep; 290(36):22049-60. PubMed ID: 26195631 [TBL] [Abstract][Full Text] [Related]
5. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200 [TBL] [Abstract][Full Text] [Related]
6. Expression of osteoprotegerin and RANK ligand in breast cancer bone metastasis. Park HR; Min SK; Cho HD; Kim DH; Shin HS; Park YE J Korean Med Sci; 2003 Aug; 18(4):541-6. PubMed ID: 12923331 [TBL] [Abstract][Full Text] [Related]
7. MKK3/6-p38 MAPK signaling is required for IL-1beta and TNF-alpha-induced RANKL expression in bone marrow stromal cells. Rossa C; Ehmann K; Liu M; Patil C; Kirkwood KL J Interferon Cytokine Res; 2006 Oct; 26(10):719-29. PubMed ID: 17032166 [TBL] [Abstract][Full Text] [Related]
8. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477 [TBL] [Abstract][Full Text] [Related]
9. BMPRIA is required for osteogenic differentiation and RANKL expression in adult bone marrow mesenchymal stromal cells. Biswas S; Li P; Wu H; Shafiquzzaman M; Murakami S; Schneider MD; Mishina Y; Li B; Li J Sci Rep; 2018 May; 8(1):8475. PubMed ID: 29855498 [TBL] [Abstract][Full Text] [Related]
10. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis. Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267 [TBL] [Abstract][Full Text] [Related]
11. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151 [TBL] [Abstract][Full Text] [Related]
12. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment. Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935 [TBL] [Abstract][Full Text] [Related]
13. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway. Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114 [TBL] [Abstract][Full Text] [Related]
14. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Sung B; Oyajobi B; Aggarwal BB Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419 [TBL] [Abstract][Full Text] [Related]
15. Sophorae Flos extract inhibits RANKL-induced osteoclast differentiation by suppressing the NF-κB/NFATc1 pathway in mouse bone marrow cells. Kim JM; Lee JH; Lee GS; Noh EM; Song HK; Gu DR; Kim SC; Lee SH; Kwon KB; Lee YR BMC Complement Altern Med; 2017 Mar; 17(1):164. PubMed ID: 28335757 [TBL] [Abstract][Full Text] [Related]
16. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength. Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532 [TBL] [Abstract][Full Text] [Related]
17. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice. Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165 [TBL] [Abstract][Full Text] [Related]
18. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways. Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102 [TBL] [Abstract][Full Text] [Related]
19. Bone morphogenetic protein 6 (BMP6) and BMP7 inhibit estrogen-induced proliferation of breast cancer cells by suppressing p38 mitogen-activated protein kinase activation. Takahashi M; Otsuka F; Miyoshi T; Otani H; Goto J; Yamashita M; Ogura T; Makino H; Doihara H J Endocrinol; 2008 Dec; 199(3):445-55. PubMed ID: 18780779 [TBL] [Abstract][Full Text] [Related]
20. Zerumbone abolishes RANKL-induced NF-kappaB activation, inhibits osteoclastogenesis, and suppresses human breast cancer-induced bone loss in athymic nude mice. Sung B; Murakami A; Oyajobi BO; Aggarwal BB Cancer Res; 2009 Feb; 69(4):1477-84. PubMed ID: 19190327 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]